Medivation, Inc. (MDVN) announced that its on-going clinical trial (phase I & II) of MDV3100 in castrate resistant prostate cancer has demonstrated both efficacy and safety in its current trials. The drug under study, MDV3100, is novel androgen receptor antagonist. This trial tracked 114 prostate cancer survivors who are hormone resistant (CRPC) for 12 weeks [...]
Researchers at Purdue have developed what they have described as prostate cancer “homing device.” They believe that this treatment modality can improve detection, and allow for the first targeted treatment of prostate cancer. The researchers have synthesized a molecule that finds and penetrates only prostate cancer cells. They have also created imaging agents and therapeutic [...]
Men with advanced prostate cancer who develop an adrenal tumor will usually undergo laparoscopic adrenalectomy (removal of the adrenal gland) as a treatment method. Just like with prostate surgery. in some situations surgery might not be the best alternative for an individual man. An individual case was recently completed at the Department of Renal and [...]
There is a new study that shows that an alpha-particle emitting radiopeptide—radioactive material bound to a synthetic peptide, a component of protein—is effective for treating prostate cancer in mice, according to researchers. The conclusions of this study could eventually (still years away if it also works in men) result in a significant breakthrough in advanced [...]
The American Association of Cancer Researchers (AACR) is in the midst of its annual scientific research meeting in Denver Colorado. As interesting prostate cancer specific information becomes available I will try and share the news. One of the biggest concerns we face in prostate cancer is in deciding when a cancer needs to be treated. [...]